The large volume requirements for high quality AB0 and RhD typing reagents can now be supplied by selected monoclonal antibodies. Superior anti-A and anti-B monoclonal reagents are each prepared from blends of two antibodies to optimise the intensity of agglutination for slide tests and the potency for detection of the weaker sub-groups, including Ax and Bw by tube techniques. Excellent anti-A,B reagents must also be made by blends of at least two antibodies to optimise both A and B reactions, but the need for their continued use is now debatable. The development of high titre IgM monoclonal anti-D reagents offers simple rapid saline RhD typing of both patients and donors, but they cannot reliably detect weak D (Du) and some D variants (Cat. VI). However, this can be achieved by blending IgG (polyclonal) anti-D with the IgM anti-D which can detect these types (in donor bloods) after conversion of negative saline tests to an antiglobulin phase. Selected monoclonal anti-complement blended with conventional anti-IgG can provide excellent polyspecific anti-human globulin reagents free of 'false positives' in routine tests. Monoclonal anti-M and -N require careful pH adjustment for optimum reactions. All anti-N reagents must be carefully diluted for reliable detection of heterozyotes, but with freedom of cross reaction with S + MM cells that have the most 'N' that is not a product of the N gene. Specific anti-M monoclonal antibodies can occur and an example is described that does not agglutinate NN cells even as a neat supernatant.
Download full-text PDF |
Source |
---|
Blood
December 2024
Sanquin, Amsterdam, Netherlands.
Alloimmunization during pregnancy occurs when a mother produces antibodies against fetal antigens, leading to complications like hemolytic disease of the fetus and newborn (HDFN) and fetal and neonatal alloimmune thrombocytopenia (FNAIT). HDFN involves destruction of fetal red blood cells, potentially causing severe anemia, hydrops fetalis, and fetal death. FNAIT affects fetal platelets and possibly endothelial cells, resulting in risk of intracranial hemorrhage and brain damage.
View Article and Find Full Text PDFCureus
December 2024
Immunohematology and Blood Transfusion, Kalinga Institute of Medical Sciences, Bhubaneswar, IND.
Background and objective RhD variants show altered D antigen expression, affecting their serological detection. Proper identification is crucial due to potential anti-D antibody formation. This study aimed to retrospectively analyze the frequency and characteristics of D variant cases encountered during RhD typing in both blood donors and recipients and the transfusion implications.
View Article and Find Full Text PDFZhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
Blood Group Reference Laboratory, Ningxia Blood Center, Yinchuan 750000, Ningxia Hui Autonomous Region, China.
Objective: To investigate the cause of the production of anti-D and anti-E mixed antibody in an RhD positive patient.
Methods: The ABO/Rh blood group typing and irregular antibody specificity were identified by conventional serological methods, the gene exon 1-10 and heterozygous analysis were performed by sequence-specific primer polymerase chain reaction (PCR-SSP), and the whole exon sequence was analyzed by first-generation sequencing.
Results: The patient's Rh blood group was weak D Type33, with the allele was , the patients was found to be heterozygous, with an Rh typing of Ccee, and the patient had developed anti-D combined with anti-E mixed antibodies.
Immunohematology
December 2024
Versiti, Milwaukee, WI.
Variant D antigens can cause variable serologic results when typing with Anti-D reagents. There is limited information regarding the ability of Anti-D reagents to differentiate between D variants defined by genotyping. This study was performed to determine if a panel of 20 U.
View Article and Find Full Text PDFVox Sang
December 2024
Clinical Laboratory Advise, Sanquin Diagnostic Services, Sanquin, Amsterdam, The Netherlands.
Background And Objectives: To test the performance of a new droplet digital polymerase chain reaction (ddPCR) non-invasive foetal blood group and platelet antigen genotyping assay in the setting of a Dutch reference laboratory for foetal blood group and platelet antigen genotyping. Our population comprised 229 consecutive alloimmunized pregnant women who presented between April 2022 and March 2023 with 250 requests for non-invasive foetal RHD, RHE, RHc, RHC, K1, HPA-1a or HPA-5b blood group and platelet antigen genotyping.
Materials And Methods: Samples were genotyped for blood group and platelet antigen alleles along with methylated RASSF1a (mRASSF1a) and sex-determining region of Y (SRY) and DYS14 as positive foetal controls.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!